Combined Immune‐Peptide Nanofiber with HSP70/AKT/mTOR Axis Blockade Enhances Photothermal Immunotherapy, Inhibiting Tumor Growth and Recurrence
Open Access
- 25 October 2026
- journal article
- research article
- Published by Wiley in Advanced Science
- p. e78434
Abstract
Although immune checkpoint blockade (ICB) therapies have shown clinical benefit, ICBs exert limited effects on most “immune‐cold” solid tumors, i.e., tumors with low immune infiltration. Photothermal immunotherapy (PTIT) converts “cold” tumors into “hot” tumors, thereby enhancing immune responses and improving ICB efficacy. Hence, developing a strategy that can integrate PTIT and ICB treatment is desirable. In this study, we designed a unique carrier‐free PSP@IR‐CF 3 nanofiber, self‐assembled from the programmed death‐ligand 1 (PD‐L1) targeting immune‐peptide NTGYFYGDQ (PSP) and a PTIT agent (IR‐CF 3 ). The nanofibers enable precise tumor targeting and immune checkpoint inhibition by specifically binding to PD‐L1 on the tumor cell surface, also providing an NIR‐mediated photothermal effect. Combining PSP@IR‐CF 3 nanofibers with NIR induced mild PTIT, which effectively activated the tumor immune microenvironment and suppressed tumor growth with lower immunotoxicity. Additionally, we identified activation of the heat shock protein 70 (HSP70) /AKT/mTOR axis following PTIT, suggesting a potential role in post‐treatment tumor survival and recurrence. By incorporating the mTOR inhibitor rapamycin, the combination treatment further enhanced therapeutic efficacy and reduced tumor recurrence.Keywords
Funding Information
- Natural Science Foundation of Beijing Municipality (7254548)
- Natural Science Foundation of Beijing Municipality (7252292)
- Natural Science Foundation of Beijing Municipality (7244524)
- National Natural Science Foundation of China (U24A20731)
- National Natural Science Foundation of China (81227901)
- National Natural Science Foundation of China (81930053)
- National Natural Science Foundation of China (62027901)
- National Natural Science Foundation of China (32101153)
- National Natural Science Foundation of China (82502418)
- Beijing Nova Program (20240484650)
- Natural Science Foundation of Shandong Province (ZR2025LZL007)
This publication has 55 references indexed in Scilit:
- Self‐Assembled Peptide‐Derived Proteolysis‐Targeting Chimera (PROTAC) Nanoparticles for Tumor‐Targeted and Durable PD‐L1 Degradation in Cancer ImmunotherapyAngewandte Chemie, 2024
- Immunologic tumor microenvironment modulators for turning cold tumors hotCancer Communications, 2024
- A Transformable Supramolecular Bispecific Cell Engager for Augmenting Natural Killer and T Cell‐Based Cancer ImmunotherapyAdvanced Materials, 2023
- Laser‐Activatable In Situ Vaccine Enhances Cancer‐Immunity CycleAdvanced Materials, 2023
- Tailored Cross‐β Assemblies Establish Peptide “Dominos” Structures for Anchoring Undruggable PharmacophoresAngewandte Chemie International Edition, 2022
- Stimuli‐Responsive Nanoparticles for Controlled Drug Delivery in Synergistic Cancer ImmunotherapyAdvanced Science, 2021
- Supramolecular Nanofibrils Formed by Coassembly of Clinically Approved Drugs for Tumor Photothermal ImmunotherapyAdvanced Materials, 2021
- Solutions to the Drawbacks of Photothermal and Photodynamic Cancer TherapyAdvanced Science, 2021
- Photosensitizer Micelles Together with IDO Inhibitor Enhance Cancer Photothermal Therapy and ImmunotherapyAdvanced Science, 2018
- Inhibition of HSP70: A challenging anti-cancer strategyCancer Letters, 2012